Pasithea Therapeutics Corp. ( KTTA) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 4:00 PM EST ...
VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, ...
But new research is finding that these so-called "monogenic diseases" actually aren't caused by single gene mutations at all. In fact, plenty of perfectly healthy people are walking around with these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results